1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1001/jama.290.13.1757" target="_blank" rel="noreferrer">http://doi.org/10.1001/jama.290.13.1757</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial
Publisher
An entity responsible for making the resource available
Jama
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
Subject
The topic of the resource
Female; Humans; Male; Pain Measurement; Adult; Analgesics; Middle Aged; Double-Blind Method; Cross-Over Studies; Non-U.S. Gov't; Research Support; Chronic disease; Hyperalgesia/complications/drug therapy; Non-Narcotic/therapeutic use; Pain/complications/drug therapy; Tetrahydrocannabinol/analogs & derivatives/therapeutic use
Creator
An entity primarily responsible for making the resource
Karst M; Salim K; Burstein S; Conrad I; Hoy L; Schneider U
Description
An account of the resource
CONTEXT: 1',1'dimethylheptyl-Delta8-tetrahydrocannabinol-11-oic acid (CT-3), a potent analog of THC-11-oic acid, produces marked antiallodynic and analgesic effects in animals without evoking the typical effects described in models of cannabinoids. Therefore, CT-3 may be an effective analgesic for poorly controlled resistant neuropathic pain. OBJECTIVE: To examine the analgesic efficacy and safety of CT-3 in chronic neuropathic pain in humans. DESIGN AND SETTING: Randomized, placebo-controlled, double-blind crossover trial conducted in Germany from May-September 2002. PARTICIPANTS: Twenty-one patients (8 women and 13 men) aged 29 to 65 years (mean, 51 years) who had a clinical presentation and examination consistent with chronic neuropathic pain (for at least 6 months) with hyperalgesia (n = 21) and allodynia (n = 7). INTERVENTIONS: Patients were randomized to two 7-day treatment orders in a crossover design. Two daily doses of CT-3 (four 10-mg capsules per day) or identical placebo capsules were given during the first 4 days and 8 capsules per day were given in 2 daily doses in the following 3 days. After a washout and baseline period of 1 week each, patients crossed over to the second 7-day treatment period. MAIN OUTCOME MEASURES: Visual analog scale (VAS) and verbal rating scale scores for pain; vital sign, hematologic and blood chemistry, and electrocardiogram measurements; scores on the Trail-Making Test and the Addiction Research Center Inventory-Marijuana scale; and adverse effects. RESULTS: The mean differences over time for the VAS values in the CT-3-placebo sequence measured 3 hours after intake of study drug differed significantly from those in the placebo-CT-3 sequence (mean [SD], -11.54 [14.16] vs 9.86 [21.43]; P =.02). Eight hours after intake of the drug, the pain scale differences between groups were less marked. No dose response was observed. Adverse effects, mainly transient dry mouth and tiredness, were reported significantly more often during CT-3 treatment (mean [SD] difference, -0.67 [0.50] for CT-3-placebo sequence vs 0.10 [0.74] for placebo-CT-3 sequence; P =.02). There were no significant differences with respect to vital signs, blood tests, electrocardiogram, Trail-Making Test, and Addiction Research Center Inventory-Marijuana scale. No carryover or period effects were observed except on the Trail-Making Test. CONCLUSIONS: In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo. No major adverse effects were observed.
2003
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1001/jama.290.13.1757" target="_blank" rel="noreferrer">10.1001/jama.290.13.1757</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2003
Adult
Analgesics
Backlog
Burstein S
Chronic Disease
Conrad I
Cross-Over Studies
Double-Blind Method
Female
Hoy L
Humans
Hyperalgesia/complications/drug therapy
JAMA
Journal Article
Karst M
Male
Middle Aged
Non-Narcotic/therapeutic use
Non-U.S. Gov't
Pain Measurement
Pain/complications/drug therapy
Research Support
Salim K
Schneider U
Tetrahydrocannabinol/analogs & derivatives/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1016/0304-3959(94)90084-1" target="_blank" rel="noreferrer">http://doi.org/10.1016/0304-3959(94)90084-1</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists
Publisher
An entity responsible for making the resource available
Pain
Date
A point or period of time associated with an event in the lifecycle of the resource
1994
Subject
The topic of the resource
Child; Female; Humans; Male; Adult; Analgesics; Aged; Middle Aged; Pain/complications/drug therapy; Neoplasms/complications; Delayed-Action Preparations; Methadone/therapeutic use; Narcotics/therapeutic use; Hyperalgesia/chemically induced/psychology; Meperidine/analogs & derivatives/therapeutic use; Morphine/administration & dosage/adverse effects/therapeutic use; Myoclonus/chemically induced; Opioid/therapeutic use; Sufentanil/therapeutic use
Creator
An entity primarily responsible for making the resource
Sjogren P; Jensen NH; Jensen TS
Description
An account of the resource
Hyperalgesia and allodynia in 4 cancer patients treated with morphine disappeared after discontinuing or substituting morphine with other opioid agonists. The first case describes a young female who developed hyperalgesia and myoclonus during intravenous morphine infusion. The hyperalgesia and myoclonus disappeared when the morphine administration was discontinued and she felt comfortable on small and sporadic oral doses of methadone. The second case describes hyperalgesia occurring after a small dose of sustained-release morphine which disappeared after alternative use of oral ketobemidone. The third case describes hyperalgesia following high doses of intramuscular morphine which disappeared after alternative use of continuous subcutaneous infusion of sufentanil. The fourth case describes a boy developing hyperalgesia after high doses of oral and intramuscular morphine. The hyperalgesia disappeared after discontinuing morphine administration but withdrawal symptoms developed due to too small doses of methadone. Possible mechanisms of morphine-induced hyperalgesia are discussed.
1994
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/0304-3959(94)90084-1" target="_blank" rel="noreferrer">10.1016/0304-3959(94)90084-1</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1994
Adult
Aged
Analgesics
Backlog
Child
Delayed-Action Preparations
Female
Humans
Hyperalgesia/chemically induced/psychology
Jensen NH
Jensen TS
Journal Article
Male
Meperidine/analogs & derivatives/therapeutic use
Methadone/therapeutic use
Middle Aged
Morphine/administration & dosage/adverse effects/therapeutic use
Myoclonus/chemically induced
Narcotics/therapeutic use
Neoplasms/complications
Opioid/therapeutic use
Pain
Pain/complications/drug therapy
Sjogren P
Sufentanil/therapeutic use